Volume 63, Issue 1, Pages (January 2013)

Slides:

Advertisements

Similar presentations

The long term outcome of high risk non-muscle invasive bladder cancer. F Thomas, N Rubin, J Goepel, D Rosario, MF Abbod, JWF Catto. Academic unit of Urology,

Advertisements

Volume 68, Issue 4, Pages (October 2015)

Volume 58, Issue 3, Pages (September 2010)

Volume 71, Issue 6, Pages (June 2017)

Volume 64, Issue 3, Pages (September 2013)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 2, Pages (August 2010)

Volume 66, Issue 6, Pages (December 2014)

Volume 58, Issue 1, Pages (July 2010)

Volume 70, Issue 6, Pages (December 2016)

The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks Marcus G.

Volume 60, Issue 2, Pages (August 2011)

Volume 73, Issue 2, Pages (February 2018)

European Urology Oncology

Volume 73, Issue 1, Pages (January 2018)

Volume 61, Issue 5, Pages (May 2012)

Volume 53, Issue 5, Pages (May 2008)

Volume 68, Issue 3, Pages (September 2015)

Volume 69, Issue 1, Pages (January 2016)

Volume 51, Issue 3, Pages (March 2007)

European Urology Oncology

Volume 60, Issue 1, Pages (July 2011)

Volume 66, Issue 6, Pages (December 2014)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Volume 72, Issue 5, Pages (November 2017)

Volume 51, Issue 5, Pages (May 2007)

Volume 72, Issue 5, Pages (November 2017)

Re: Marcus G. Cumberbatch, Matteo Rota, James W. F

Volume 63, Issue 4, Pages (April 2013)

Volume 59, Issue 2, Pages (February 2011)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 61, Issue 2, Pages (February 2012)

Bladder Cancer: A Major Public Health Issue

Volume 66, Issue 2, Pages (August 2014)

Volume 71, Issue 6, Pages (June 2017)

What is New in Bladder Cancer Diagnosis and Management?

Volume 68, Issue 5, Pages (November 2015)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 61, Issue 5, Pages (May 2012)

Volume 52, Issue 5, Pages (November 2007)

Volume 61, Issue 4, Pages (April 2012)

Volume 53, Issue 4, Pages (April 2008)

Volume 67, Issue 3, Pages (March 2015)

Volume 64, Issue 5, Pages (November 2013)

Volume 61, Issue 6, Pages (June 2012)

Volume 71, Issue 6, Pages (June 2017)

Volume 64, Issue 4, Pages (October 2013)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 66, Issue 6, Pages (December 2014)

Volume 66, Issue 6, Pages (December 2014)

Volume 61, Issue 2, Pages (February 2012)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Volume 61, Issue 6, Pages (June 2012)

Volume 47, Issue 1, Pages (January 2005)

Volume 53, Issue 1, Pages (January 2008)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 68, Issue 4, Pages (October 2015)

Volume 71, Issue 5, Pages (May 2017)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

European Urology is “Your” Journal

Epidemiology of Renal Cell Carcinoma

Volume 54, Issue 1, Pages (July 2008)

Volume 52, Issue 4, Pages (October 2007)

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Volume 53, Issue 2, Pages (February 2008)

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Volume 52, Issue 1, Pages (July 2007)

Volume 54, Issue 1, Pages (July 2008)

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? Shahrokh Shariat, Paolo Gontero, James.

Presentation transcript:

Volume 63, Issue 1, Pages 145-154 (January 2013) Comparative Outcomes of Primary, Recurrent, and Progressive High-risk Non–muscle- invasive Bladder Cancer Francis Thomas, Aidan P. Noon, Naomi Rubin, John R. Goepel, James W.F. Catto European Urology Volume 63, Issue 1, Pages 145-154 (January 2013) DOI: 10.1016/j.eururo.2012.08.064 Copyright © 2012 Terms and Conditions

Fig. 1 The grouping and exclusion strategy for tumours within this study. MIBC=muscle-invasive bladder cancer; RHH=Royal Hallamshire Hospital; UCC=urothelial cell carcinoma. European Urology 2013 63, 145-154DOI: (10.1016/j.eururo.2012.08.064) Copyright © 2012 Terms and Conditions

Fig. 2 The natural history of primary, progressive, and recurrent high-risk non–muscle-invasive bladder tumours. MIBC=muscle-invasive bladder cancer; DSM=disease-specific mortality. European Urology 2013 63, 145-154DOI: (10.1016/j.eururo.2012.08.064) Copyright © 2012 Terms and Conditions

Fig. 3 Progression-free, disease-specific, and other-cause specific survival stratified by tumour grouping in (a) all patients, (b) those with no invasion (pTa and pTis), and (c) those with lamina propria invasion (pT1). Data were plotted using the Kaplan-Meier method. DSM=disease-specific mortality; OCM=other-cause mortality. European Urology 2013 63, 145-154DOI: (10.1016/j.eururo.2012.08.064) Copyright © 2012 Terms and Conditions